Effect of thyroxine supplementation on the response to perfluoro‐<i>n</i>‐decanoic acid (PFDA) in rats

Gutshall, Denise M.; Pilcher, Gary D.; Langley, Albert E.

doi:10.1080/15287398809531179

Cited by 19 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early studies of the effects of PFAAs in rodents showed that a single dose lowered heart rate and body temperature and depressed T 4 and T 3 . Replacement of T 4 did not reverse the clinical symptoms of hypothermia (Gutshall et al 1988; Langley and Pilcher 1985). Although circulating thyroid hormone levels were low, liver enzymes responsive to thyroid hormone levels were elevated, suggesting that thyroidal homeostasis was not functionally compromised.…”

Section: Discussionmentioning

confidence: 90%

Association between Serum Perfluorooctanoic Acid (PFOA) and Thyroid Disease in the U.S. National Health and Nutrition Examination Survey

Melzer

Rice

Depledge

et al. 2010

Environ Health Perspect

429

291

View full text Add to dashboard Cite

BackgroundPerfluorooctanoic acid (PFOA, also known as C8) and perfluorooctane sulfonate (PFOS) are stable compounds with many industrial and consumer uses. Their persistence in the environment plus toxicity in animal models has raised concern over low-level chronic exposure effects on human health.ObjectivesWe estimated associations between serum PFOA and PFOS concentrations and thyroid disease prevalence in representative samples of the U.S. general population.MethodsAnalyses of PFOA/PFOS versus disease status in the National Health and Nutrition Examination Survey (NHANES) for 1999–2000, 2003–2004, and 2005–2006 included 3,974 adults with measured concentrations for perfluorinated chemicals. Regression models were adjusted for age, sex, race/ethnicity, education, smoking status, body mass index, and alcohol intake.ResultsThe NHANES-weighted prevalence of reporting any thyroid disease was 16.18% (n = 292) in women and 3.06% (n = 69) in men; prevalence of current thyroid disease with related medication was 9.89% (n = 163) in women and 1.88% (n = 46) in men. In fully adjusted logistic models, women with PFOA ≥ 5.7 ng/mL [fourth (highest) population quartile] were more likely to report current treated thyroid disease [odds ratio (OR) = 2.24; 95% confidence interval (CI), 1.38–3.65; p = 0.002] compared with PFOA ≤ 4.0 ng/mL (quartiles 1 and 2); we found a near significant similar trend in men (OR = 2.12; 95% CI, 0.93–4.82; p = 0.073). For PFOS, in men we found a similar association for those with PFOS ≥ 36.8 ng/mL (quartile 4) versus ≤ 25.5 ng/mL (quartiles 1 and 2: OR for treated disease = 2.68; 95% CI, 1.03–6.98; p = 0.043); in women this association was not significant.ConclusionsHigher concentrations of serum PFOA and PFOS are associated with current thyroid disease in the U.S. general adult population. More work is needed to establish the mechanisms involved and to exclude confounding and pharmacokinetic explanations.

show abstract

Section: Discussionmentioning

confidence: 90%

Association between Serum Perfluorooctanoic Acid (PFOA) and Thyroid Disease in the U.S. National Health and Nutrition Examination Survey

Melzer

Rice

Depledge

et al. 2010

Environ Health Perspect

429

291

View full text Add to dashboard Cite

show abstract

“…It has been discussed, if the mechanism of the rapid decreasing effect of PFDA on the T, and T4 levels in the serum of the rat is central (Langley & Pilcher 1985). On the other hand, it is obvious, that PFDA is able to displace T4 from the rat serum albumin (Gutshall et al 1988) as well as from the human serum albumin in vitro (own unpublished results), which may interfere the T, transport in the serum.…”

Section: Discussionmentioning

confidence: 98%

Tissue Distribution and Elimination of Perfluorodecanoic Acid in the Rat after Single Intraperitoneal Administration

Ylinen

Auriola

1990

Pharmacology & Toxicology

View full text Add to dashboard Cite

Tissue distribution, metabolism, and excretion of perfluorodecanoic acid (PFDA) after a single intraperitoneal dose (20 mg/kg) were studied in female and male Wistar rats. PFDA accumulated in the serum and tissues of the rats. In the serum, more than 99% of PFDA was bound by the serum proteins. In the liver, anionic and esterified PFDA were detected. Metabolic oxidation of PFDA was not observed. PFDA was not excreted in urine either by females or males during 14 days after the administration. At the same time, about 0.5% of the administered PFDA dose was excreted daily in the faeces by both sexes. In spite of the analogical structure with perfluorooctanoic acid (PFOA), which is rapidly eliminated in urine by the female rats, PFDA accumulated similarly in females and males. The reduced elimination of PFDA partially explains its greater toxicity to rats in comparison with PFOA.

show abstract

“…The first reports of the effect of PFCs on thyroid hormones were from Langley and Pilcher [195] and Gutshall et al [196]. Rats that had received a dose of PFDA were found to have significantly reduced T 4 and T 5 concentrations, lower body temperature, and a slower heartbeat than control animals.…”

Section: Effects On the Endocrine Systemmentioning

confidence: 99%

Toxicology of perfluorinated compounds

2011

View full text Add to dashboard Cite

Perfluorinated compounds [PFCs] have found a wide use in industrial products and processes and in a vast array of consumer products. PFCs are molecules made up of carbon chains to which fluorine atoms are bound. Due to the strength of the carbon/fluorine bond, the molecules are chemically very stable and are highly resistant to biological degradation; therefore, they belong to a class of compounds that tend to persist in the environment. These compounds can bioaccumulate and also undergo biomagnification. Within the class of PFC chemicals, perfluorooctanoic acid and perfluorosulphonic acid are generally considered reference substances. Meanwhile, PFCs can be detected almost ubiquitously, e.g., in water, plants, different kinds of foodstuffs, in animals such as fish, birds, in mammals, as well as in human breast milk and blood. PFCs are proposed as a new class of 'persistent organic pollutants'. Numerous publications allude to the negative effects of PFCs on human health. The following review describes both external and internal exposures to PFCs, the toxicokinetics (uptake, distribution, metabolism, excretion), and the toxicodynamics (acute toxicity, subacute and subchronic toxicities, chronic toxicity including carcinogenesis, genotoxicity and epigenetic effects, reproductive and developmental toxicities, neurotoxicity, effects on the endocrine system, immunotoxicity and potential modes of action, combinational effects, and epidemiological studies on perfluorinated compounds).

show abstract

Effect of thyroxine supplementation on the response to perfluoro‐n‐decanoic acid (PFDA) in rats

Cited by 19 publications

References 7 publications

Association between Serum Perfluorooctanoic Acid (PFOA) and Thyroid Disease in the U.S. National Health and Nutrition Examination Survey

Association between Serum Perfluorooctanoic Acid (PFOA) and Thyroid Disease in the U.S. National Health and Nutrition Examination Survey

Tissue Distribution and Elimination of Perfluorodecanoic Acid in the Rat after Single Intraperitoneal Administration

Toxicology of perfluorinated compounds

Contact Info

Product

Resources

About